As of the end of 2020, coronavirus disease 2019 (COVID-19) remains a global healthcare
challenge with alarming death tolls. In the absence of targeted therapies, supportive care
continues to be the mainstay of treatment. The hallmark of severe COVID-19 is a
thromboinflammatory storm driven by innate immune responses. This manifests clinically as
acute respiratory distress syndrome, and in some patients, widespread thrombotic
microangiopathy. Neutrophils and complement are key players in the innate immune …